J. Safra Sarasin Holding AG Has $681,000 Stake in Annexon, Inc. $ANNX

by · The Markets Daily

J. Safra Sarasin Holding AG lowered its stake in shares of Annexon, Inc. (NASDAQ:ANNX – Free Report) by 41.5% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 223,221 shares of the company’s stock after selling 158,220 shares during the period. J. Safra Sarasin Holding AG’s holdings in Annexon were worth $681,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Matauro LLC bought a new position in Annexon during the second quarter valued at about $27,000. 49 Wealth Management LLC acquired a new stake in shares of Annexon during the 2nd quarter worth approximately $29,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Annexon during the second quarter valued at approximately $29,000. Engineers Gate Manager LP bought a new stake in shares of Annexon during the second quarter valued at approximately $32,000. Finally, SG Americas Securities LLC acquired a new position in shares of Annexon in the third quarter valued at $34,000.

Annexon Stock Up 3.7%

Shares of Annexon stock opened at $6.52 on Friday. The stock has a market capitalization of $779.99 million, a P/E ratio of -4.62 and a beta of 1.19. Annexon, Inc. has a 12-month low of $1.28 and a 12-month high of $7.18. The company has a 50-day simple moving average of $5.27 and a 200 day simple moving average of $3.60.

Annexon (NASDAQ:ANNX – Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, equities analysts anticipate that Annexon, Inc. will post -0.96 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on ANNX. Chardan Capital began coverage on shares of Annexon in a research note on Tuesday, December 23rd. They set a “buy” rating and a $16.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a research report on Wednesday, January 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research note on Wednesday, January 14th. Finally, Wells Fargo & Company raised their price target on shares of Annexon from $14.00 to $27.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.00.

View Our Latest Stock Analysis on ANNX

Insider Buying and Selling at Annexon

In other Annexon news, Director Muneer A. Satter purchased 500,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The stock was acquired at an average cost of $3.94 per share, with a total value of $1,970,000.00. Following the completion of the acquisition, the director directly owned 8,906,024 shares of the company’s stock, valued at $35,089,734.56. This represents a 5.95% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jung Choi acquired 33,000 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were bought at an average cost of $4.19 per share, for a total transaction of $138,270.00. Following the acquisition, the director owned 33,000 shares in the company, valued at approximately $138,270. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 1,863,843 shares of company stock valued at $7,243,105. Corporate insiders own 11.87% of the company’s stock.

Annexon Company Profile

(Free Report)

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.

Further Reading

Want to see what other hedge funds are holding ANNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Annexon, Inc. (NASDAQ:ANNX – Free Report).